Literature DB >> 33165818

Long-term outcomes of left atrial appendage occlusion in high-risk atrial fibrillation patients: 4-year follow up data.

Wern Yew Ding1, Gregory Y H Lip1,2, Stefano Bartoletti3, Lindsay Morrison3, Afshin Khalatbari3, Suneil Aggarwal3, Periaswamy Velavan3, Dhiraj Gupta4.   

Abstract

Long-term follow-up data of left atrial appendage (LAA) occlusion in patients with atrial fibrillation (AF) are sparse. To address these data gaps, we analysed the 4-year outcomes of AF patients following LAA occlusion. The was a retrospective cohort study of high-risk patients with AF who underwent successful implantation of the Amulet device at our center between 2014 and 2017. Study endpoints were the rate of stroke, major bleeding and all-cause mortality. We included 71 patients (35.2% females) with a median age of 78 (IQR 73-82) years. Over a median follow-up period of 46 (IQR 19-56) months, the annual rate of ischemic stroke was 1.06 events/100 patient-years (95% CI 0-2.35), hemorrhagic stroke was 1.06 events/100 patient-years (95% CI 0-2.35) and major extracranial bleeding that required unplanned hospital admission was 1.84 events/100 patient-years (95% CI 0.25-3.43). A total of 28 (39.4%) patients died during this period with an annual mortality rate of 10.29 events/100 patient-years (95% CI 7.25-13.32). Our experience suggests that LAA occlusion using the Amulet device appears to be associated with a low risk of ischemic stroke in high-risk AF patients who are deemed unsuitable for oral anticoagulation; however, these patients have a high rate of mortality over the medium to long-term follow-up, and an ongoing significant risk of bleeding and thrombotic events.

Entities:  

Keywords:  Atrial fibrillation; Left atrial appendage; Mortality; Occlusion; Stroke

Mesh:

Year:  2020        PMID: 33165818     DOI: 10.1007/s11239-020-02333-y

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  7 in total

1.  Interventional occlusion of left atrial appendage in patients with atrial fibrillation. Acute and long-term outcome of occluder implantation in the LAARGE Registry.

Authors:  Johannes Brachmann; Thorsten Lewalter; Ibrahim Akin; Horst Sievert; Volker Geist; Uwe Zeymer; Damir Erkapic; Harald Mudra; Sven Pleger; Matthias Hochadel; Jochen Senges
Journal:  J Interv Card Electrophysiol       Date:  2019-11-09       Impact factor: 1.900

2.  Left Atrial Appendage Closure in Patients With Contraindications to Oral Anticoagulation.

Authors:  Dinesh Sharma; Vivek Y Reddy; Marcus Sandri; Philipp Schulz; Nicolas Majunke; Pavel Hala; Jens Wiebe; Tomas Mraz; Marc A Miller; Petr Neuzil; Sven Möbius-Winkler; Horst Sievert; Peter Sick
Journal:  J Am Coll Cardiol       Date:  2016-05-10       Impact factor: 24.094

3.  PAK Membrane Translocation and Phosphorylation Regulate Platelet Aggregation Downstream of Gi and G12/13 Pathways.

Authors:  Jianjun Zhang; Yan Zhang; Shuang Zheng; Yangyang Liu; Lin Chang; Guanxing Pan; Liang Hu; Si Zhang; Junling Liu; Soochong Kim; Jianzeng Dong; Zhongren Ding
Journal:  Thromb Haemost       Date:  2020-08-27       Impact factor: 5.249

4.  Left atrial appendage occlusion with the Amplatzer™ Amulet™ device: full results of the prospective global observational study.

Authors:  David Hildick-Smith; Ulf Landmesser; A John Camm; Hans-Christoph Diener; Vince Paul; Boris Schmidt; Magnus Settergren; Emmanuel Teiger; Jens Erik Nielsen-Kudsk; Claudio Tondo
Journal:  Eur Heart J       Date:  2020-08-07       Impact factor: 29.983

5.  Outcomes and costs of left atrial appendage closure from randomized controlled trial and real-world experience relative to oral anticoagulation.

Authors:  Sandeep Panikker; Joanne Lord; Julian W E Jarman; Shannon Armstrong; David G Jones; Shouvik Haldar; Charles Butcher; Habib Khan; Lilian Mantziari; Edward Nicol; Wajid Hussain; Jonathan R Clague; John P Foran; Vias Markides; Tom Wong
Journal:  Eur Heart J       Date:  2016-03-01       Impact factor: 29.983

6.  5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials.

Authors:  Vivek Y Reddy; Shephal K Doshi; Saibal Kar; Douglas N Gibson; Matthew J Price; Kenneth Huber; Rodney P Horton; Maurice Buchbinder; Petr Neuzil; Nicole T Gordon; David R Holmes
Journal:  J Am Coll Cardiol       Date:  2017-11-04       Impact factor: 24.094

7.  Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation.

Authors:  Vivek Y Reddy; Ronald L Akehurst; Stacey L Amorosi; Meghan B Gavaghan; Deanna S Hertz; David R Holmes
Journal:  Stroke       Date:  2018-05-08       Impact factor: 7.914

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.